Biosenic (XPAR:BIOS) EV-to-FCF: -20.63 (As of Jul. 06, 2026)


What is Biosenic EV-to-FCF?

Biosenic XPAR:BIOS 9 EV-to-FCF is -20.63 as of Jul. 06, 2026. GuruFocus rates XPAR:BIOS with a GF Score™ of 9/100. The stock has 5 warning signs investors should review.

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biosenic's Enterprise Value is €45.81 Mil. Biosenic's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-2.22 Mil. Therefore, Biosenic's EV-to-FCF for today is -20.63.

The historical rank and industry rank for Biosenic's EV-to-FCF or its related term are showing as below:

XPAR:BIOS' s EV-to-FCF Range Over the Past 10 Years
Min: -7.17   Med: -0.35   Max: -0.01
Current: -12.17

During the past 12 years, the highest EV-to-FCF of Biosenic was -0.01. The lowest was -7.17. And the median was -0.35.

XPAR:BIOS's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 16.3 vs XPAR:BIOS: -12.17

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-06), Biosenic's stock price is €0.00. Biosenic's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €0.000. Therefore, Biosenic's PE Ratio (TTM) for today is N/A.


Biosenic  (XPAR:BIOS) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Biosenic's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.00/0.000
=N/A

Biosenic's share price for today is €0.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biosenic's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Biosenic EV-to-FCF Related Terms


Biosenic EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Biosenic's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosenic EV-to-FCF Chart

Biosenic Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.66 -13.29 -12.87 -11.02 -12.37

Biosenic Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.87 0.00 -11.02 0.00 -12.37

XPAR:BIOS vs VRTX, REGN, ALNY: EV-to-FCF Comparison

For the Biotechnology subindustry, Biosenic's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosenic EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biosenic's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Biosenic's EV-to-FCF falls into.



Biosenic EV-to-FCF Calculation

Biosenic's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=45.809/-2.221
=-20.63

Biosenic's current Enterprise Value is €45.81 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biosenic's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-2.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-FCF →
What does a EV-to-FCF of -20.63 mean?
Biosenic (XPAR:BIOS) has a EV-to-FCF of -20.63 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biosenic and its competitors.
Is Biosenic's EV-to-FCF too high?
Biosenic's current EV-to-FCF is -20.63. Overall, Biosenic has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Biosenic's EV-to-FCF compare to VRTX and REGN?
Biosenic's EV-to-FCF of -20.63 can be compared against companies in the Biotechnology industry. The industry median EV-to-FCF is 16.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.30, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biosenic and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biosenic's current EV-to-FCF is -20.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosenic stock overvalued right now?
Biosenic (XPAR:BIOS) has a current EV-to-FCF of -20.63. The current EV-to-FCF is -20.63. Biosenic's overall GF Score™ is 9/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Biosenic (XPAR:BIOS), the current EV-to-FCF is -20.63 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biosenic Business Description

Address Rue Granbonpre 11, Batiment H (bte 24), Mont-St-Guibert, BEL, 1435
Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.